IRB #

STUDY00016349

Title

[Quorum] CINC280A2201: A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

Principal Investigator

Khaled Tolba

Study Purpose

The purpose of this study is to evaluate the efficacy of the study drug, INC280, in patients with advanced EGFR wild-type Non-Small Cell Lung Cancer.

Medical Condition(s)

Non-Small Cell Lung Cancer
EGFR wild-type

Eligibility Criteria

≥ 18 years of age
Non-small cell lung cancer, Stage IIIB or IV
Previously treated with one or two prior lines of systemic therapy for advanced/metastatic disease or must not have received any systemic therapy for advanced/metastatic disease
Must not have been treated with crizotinib

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drug until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.

Minors Included

No

Contact

OHSU Knight Cancer Institute Information line 503-494-1080

Sponsor

Novartis

Recruitment End

12/31/2030

Compensation Provided

No


Go Back